The Economic Value of a Quadrivalent versus Trivalent Influenza Vaccine

Details

• Alternative Title:
  Vaccine
• Personal Author:
  Lee, Bruce Y. ; Bartsch, Sarah M. ; Willig, Alyssa M.
• Description:
  The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost-savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.
• Subjects:
  Adolescent Adult Aged Aged, 80 And Over Child Child, Preschool Costs And Cost Analysis Female Humans Infant Influenza, Human Influenza Vaccines Male Middle Aged Young Adult

  More +
• Source:
  Vaccine. 2012; 30(52):7443-7446.
• Pubmed ID:
  23084849
• Pubmed Central ID:
  PMC3696129
• Document Type:
  Journal Article
• Funding:
  1U54GM088491-0109/GM/NIGMS NIH HHS/United States ; 5P01HK000086-02/HK/PHITPO CDC HHS/United States ; 5R01LM009132-03/LM/NLM NIH HHS/United States ; R01 LM009132/LM/NLM NIH HHS/United States ; U54 GM088491/GM/NIGMS NIH HHS/United States
• Volume:
  30
• Issue:
  52
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:92d9ed62e7f9929cc8bd3af7f36d66415b50bd6d2670d55c68339b44495d1e09
• Download URL:
  https://stacks.cdc.gov/view/cdc/33590/cdc_33590_DS1.pdf
• File Type:
  [PDF - 39.54 KB ]